Dry age-related macular degeneration (AMD) gradually impairs central vision, making it harder to read, drive, or recognize faces. The FDA-authorized Valeda Light Delivery System, now offered at VRMNY in New York City, provides a non-invasive treatment that may improve contrast sensitivity, enhance visual function, and slow disease progression by stimulating cellular repair and reducing retinal inflammation—bringing new hope to patients with early to intermediate dry AMD.
The Valeda Light Therapy system represents a major advancement in retinal care. Using precise wavelengths of light, this therapy stimulates cellular activity in the retina, helping preserve vision and slow disease progression. Unlike injections or surgery, Valeda Eye Treatment is painless, quick, and performed in-office.
The Valeda system has been FDA-authorized for people with early to intermediate dry AMD, based upon recent clinical trials. These are people who still have fairly good vision (for example, between 20/30 and 20/100). It was not authorized for wet AMD, which is treated using eye injections. Further studies will be needed to see the effect of light therapy on wet AMD.
Some people with geographic atrophy, an advanced stage of dry AMD, may still benefit, especially if the damage has not fully destroyed the center of their vision. But light therapy likely won’t reverse vision loss that has already happened.
Dry age-related macular degeneration (AMD) is the most common form of AMD, caused by the gradual thinning of the macula—the part of the retina responsible for sharp central vision. It typically progresses slowly, but without intervention, it can lead to significant vision loss. Early detection and proactive care are essential.
Valeda works by using photobiomodulation (PBM), a process where specific light wavelengths stimulate cellular repair and reduce inflammation. The Valeda Light Treatment protocol involves multiple sessions over several weeks, each lasting just a few minutes.
Clinical trials of Valeda Light Therapy have shown multiple benefits for patients with early to intermediate dry AMD:
Valeda offers a new approach for managing dry AMD—especially for those looking to take action before vision loss becomes more serious.
You may be a candidate for Valeda Eye Treatment if you’ve been diagnosed with dry AMD and still retain functional central vision. The therapy is especially promising for those in the early to intermediate stages, and your ophthalmologist can guide you through eligibility and expected outcomes.
PBM is a light-based therapy that stimulates cellular repair and reduces inflammation in retinal tissue.
No, it doesn’t cure AMD, but it may slow progression and help preserve vision in early to intermediate stages.
Valeda is non-invasive and well-tolerated. Side effects are rare and typically mild, such as temporary eye discomfort.
If you or a loved one is affected by dry macular degeneration, schedule a consultation with VRMNY today. Our retina specialists will assess your condition and determine if Valeda Light Therapy is right for you. Protect your vision—early action makes all the difference.
We’re proud to serve patients across New York City, including Manhattan, Brooklyn, and Westchester. To learn more or book your appointment, call us at (212) 861-9797.
Let us help you enjoy your life
Call: (212) 861-9797To Speak With An Appointment Coordinator Now